publication venue for
- Venous thromboembolism in pediatric inflammatory bowel disease: an 11-year population-based nested case–control study in Canada. 33:449-456. 2022
- Use of thrombolytic agents to treat neonatal thrombosis in clinical practice. 33:193-200. 2022
- Epidemiology, diagnosis and management of neonatal thrombosis: a single-center cohort study. 33:83-89. 2022
- How to use low-molecular-weight heparin to treat neonatal thrombosis in clinical practice. 32:531-538. 2021
- Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography. 32:305-311. 2021
- Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography. 29:521-527. 2018
- Conservative management of neonatal cerebral sinovenous thrombosis with coexisting thrombophilia. 29:399-403. 2018
- In-vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma. 28:551-557. 2017
- Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin, and a covalent antithrombin–heparin complex. 28:431-437. 2017
- Procoagulant effects of lung cancer chemotherapy. 28:72-82. 2017
- How to use unfractionated heparin to treat neonatal thrombosis in clinical practice. 27:605-614. 2016
- The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis. 27:648-652. 2016
- Neonatal central venous catheter thrombosis: diagnosis, management, and outcome. 2016
- Risk factors for central venous catheter-related thrombosis in children. 27:384-388. 2016
- Central venous access device insertion and perioperative management of patients with severe haemophilia A. 27:156-159. 2016
- Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. 26:36-45. 2015
- Pharmacokinetics of recombinant and plasma-derived factor IX products in pediatric patients with severe hemophilia B. 26:113-114. 2015
- Effect of ascorbate on fibrinolytic factors in septic mouse skeletal muscle. 25:745-753. 2014
- Factor XIII deficiency management. 25:199-205. 2014
- Neonatal central venous catheter thrombosis. 25:97-106. 2014
- Spontaneous neonatal arterial thromboembolism. 24:787-797. 2013
- Neonatal and childhood right atrial thrombosis. 24:458-458. 2013
- Thrombosis and embolism in pediatric cardiomyopathy. 24:221-230. 2013
- Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. 24:23-27. 2013
- Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. 24:23-27. 2013
- Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation. 23:705-713. 2012
- Neonatal and infant pulmonary thromboembolism. 23:653-662. 2012
- Management of myocardial infarction in children with Kawasaki disease. 21:620-631. 2010
- Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach. 21:301-307. 2010
- Novel paediatric anticoagulants: a review of the current literature. 21:144-151. 2010
- Renal venous thrombosis in a newborn with prothrombotic risk factors. 20:458-460. 2009
- 5 flourouracil-induced apical ballooning syndrome: a case report. 20:306-308. 2009
- Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. 20:114-121. 2009
- Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation. 20:47-51. 2009
- Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. 19:471-475. 2008
- Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder. 19:463-464. 2008
- Quebec platelet disorder: features, pathogenesis and treatment. 19:109-119. 2008
- Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. 18:657-660. 2007
- Quantitative analysis of catheter roughness induced by cutting and manipulation: a potential prothrombotic risk. 18:531-536. 2007
- Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery. 18:219-225. 2007
- The tissue factor pathway in ischemic stroke. 17:527-532. 2006
- Molecular cloning and functional expression of rabbit α2-antiplasmin. 17:283-291. 2006
- The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass. 16:323-328. 2005
- Managing oral anticoagulant therapy in patients with mechanical heart valves undergoing elective surgery. 15:623-628. 2004
- Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. 15:353-357. 2004
- Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant.. 15:353-357. 2004
- Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. 15:129-130. 2004
- Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. 15:129-130. 2004
- Acquired hemophilia masked by warfarin therapy. 14:769-772. 2003
- Recombinant activated factor VII for the treatment of life-threatening haemorrhage. 14:713-717. 2003
- Venous thromboembolism in travellers. 14:671-675. 2003
- Venous thromboembolism in travellers: can we identify those at risk?. 14:671-675. 2003
- Prevention of venous thromboembolism in medical patients with enoxaparin. 14:341-346. 2003
- Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. 14:341-346. 2003
- Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease. 14:181-186. 2003
- Regulation of plasminogen activator inhibitor-1 secretion by growth factors in smooth muscle cells. 13:541-549. 2002
- Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. 13:49-52. 2002
- Prolonged in vivo anticoagulant activity of a hirudin–albumin fusion protein secreted from Pichia pastoris. 12:433-443. 2001
- Influence of exogenous factor VIIa on thrombin generation in cord plasma of full-term and pre-term newborns. 11:349-357. 2000
- Influence of activated factor VII concentrates on thrombin generation in full-term and preterm neonates. 11:S133-S134. 2000
- Prothrombin 20210A and familial thrombophilia. 10:523-527. 1999
- Anticoagulation in acute ischaemic stroke: deep vein thrombosis prevention and long-term stroke outcomes - Conclusions. 10:S129-S130. 1999
- Building a new era in DVT management. Conclusions.. 10 Suppl 2:S129-S130. 1999
- Building a new era in DVT management. Introduction.. 10 Suppl 2:S1-S3. 1999
- Customizing our approach in deep vein thrombosis and pulmonary embolism treatment: overview of our clinical experience.. 10 Suppl 2:S107-S115. 1999
- From foundations to the future: Building a new era in DVT management - Proceedings of a Meeting held in Barcelona, Spain, 26-27 June 1998 - Introduction. 10:S1-S3. 1999
- Withdrawal of warfarin after deep vein thrombosis. 10:291-296. 1999
- Familial thrombophilia and the prothrombin 20210A mutation. 10:1-6. 1999
- A novel antithrombin-heparin covalent complex. 9:587-596. 1998
- Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. 8:216-222. 1997
- Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.. 8:216-222. 1997
- Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor. 7:453-458. 1996
- Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism. 6:311-316. 1995
- Defining the heparin-binding domain of antithrombin. 5:83-96. 1994
- Microheterogeneity of antithrombin III. 5:7-16. 1994
- An overview of the mechanism of action of antithrombin and its inherited deficiency states. 5:S5-12. 1994
- Panel Discussion. 5:S59-S59. 1994
- The hypercoagulable state in cancer patients. 5:S19-23. 1994
- Evidence for thrombin binding to dermatan sulphate sites in the rabbit aorta subendothelium in vitro. 4:927-933. 1993
- Frequent association of factor VII defects with other clotting disorders. 3:829-830. 1992
- Frequent association of factor VII defects with other clotting disorders. 3:831-834. 1992
- Platelet imipramine binding is increased in essential thrombocythaemia. 3:669-672. 1992
- Thrombotic thrombocytopenic purpura. 3:655-660. 1992
- A novel congenital haemostatic defect. 3:357-360. 1992
- Thrombin structure and function. 2:69-76. 1991
- Introduction. 14:vii-vii. 1991
- Conclusion 2004
- Experiences with continuous infusion of recombinant activated factor VII. 1998
- Design and assessment of clinical trials on continuous infusion. 1996
- Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? 1996